CA2632516C - Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants - Google Patents

Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants Download PDF

Info

Publication number
CA2632516C
CA2632516C CA2632516A CA2632516A CA2632516C CA 2632516 C CA2632516 C CA 2632516C CA 2632516 A CA2632516 A CA 2632516A CA 2632516 A CA2632516 A CA 2632516A CA 2632516 C CA2632516 C CA 2632516C
Authority
CA
Canada
Prior art keywords
vaccine
dsrna
influenza
avian influenza
ampligen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2632516A
Other languages
English (en)
French (fr)
Other versions
CA2632516A1 (en
Inventor
William A. Carter
David Strayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AIM Immunotech Inc
Original Assignee
Hemispherx Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemispherx Biopharma Inc filed Critical Hemispherx Biopharma Inc
Publication of CA2632516A1 publication Critical patent/CA2632516A1/en
Application granted granted Critical
Publication of CA2632516C publication Critical patent/CA2632516C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2632516A 2005-12-07 2006-12-06 Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants Active CA2632516C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US74290605P 2005-12-07 2005-12-07
US60/742,906 2005-12-07
US75289805P 2005-12-23 2005-12-23
US60/752,898 2005-12-23
US79323906P 2006-04-20 2006-04-20
US60/793,239 2006-04-20
PCT/US2006/046356 WO2007067517A2 (en) 2005-12-07 2006-12-06 Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants

Publications (2)

Publication Number Publication Date
CA2632516A1 CA2632516A1 (en) 2007-06-14
CA2632516C true CA2632516C (en) 2018-05-15

Family

ID=38123418

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2632516A Active CA2632516C (en) 2005-12-07 2006-12-06 Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants

Country Status (6)

Country Link
US (3) US7943147B2 (enExample)
EP (1) EP1957101A4 (enExample)
JP (2) JP2009518410A (enExample)
AU (1) AU2006322073A1 (enExample)
CA (1) CA2632516C (enExample)
WO (1) WO2007067517A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009337A2 (en) * 2003-05-16 2005-02-03 Hemispherx Biopharma Treating severe acute respiratory syndrome
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
JP2009518410A (ja) * 2005-12-07 2009-05-07 へミスフェリックス・バイオファーマ インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ
AU2008266910A1 (en) * 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100310600A1 (en) * 2008-02-15 2010-12-09 Carter William A Selective agonist of toll-like receptor 3
EP2271361A1 (en) * 2008-04-16 2011-01-12 Université de Lausanne Method and vaccine for optimizing the specific immune responses
JP5715051B2 (ja) * 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
EP2413961B1 (en) * 2009-03-31 2016-08-17 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
EP4023244A4 (en) * 2019-08-28 2023-11-01 NA Vaccine Institute INFLUENZA VACCINE COMPOSITION BASED ON A NOVEL NUCLEIC ACID

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)
US5132292A (en) * 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
GB0119346D0 (en) * 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
WO2005014038A1 (ja) 2003-08-11 2005-02-17 The Research Foundation For Microbial Diseases Of Osaka University 粘膜免疫誘導アジュバントを含む新規ワクチン
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
JP2009518410A (ja) * 2005-12-07 2009-05-07 へミスフェリックス・バイオファーマ インフルエンザウイルスワクチンアジュバントまたは免疫‐刺激因子としてのｄｓＲＮＡ
CN101652062A (zh) 2007-03-05 2010-02-17 犹他州立大学 Toll样受体3(TLR3)的限制性激动剂

Also Published As

Publication number Publication date
US7943147B2 (en) 2011-05-17
US20070224219A1 (en) 2007-09-27
US20150064216A1 (en) 2015-03-05
US20110223198A1 (en) 2011-09-15
EP1957101A2 (en) 2008-08-20
WO2007067517A3 (en) 2008-01-31
WO2007067517A2 (en) 2007-06-14
JP2009518410A (ja) 2009-05-07
CA2632516A1 (en) 2007-06-14
JP2013075920A (ja) 2013-04-25
EP1957101A4 (en) 2010-04-07
AU2006322073A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
US20150064216A1 (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
JP6308500B2 (ja) 強化された免疫賦活化剤
JP2003523310A (ja) 新規インフルエンザウイルスワクチン組成物
Goetz et al. Vaccine adjuvants for infectious disease in the clinic
US10881723B2 (en) Vaccine containing immobilized virus particles
Kumar et al. Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus
Luan et al. LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix™ in VZV-primed mice
CN109701010B (zh) 疫苗复合佐剂系统及其在抗原中的应用
Hongtu et al. Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice
Hoover et al. N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infection
AU2013206335B2 (en) dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
S Almeida et al. Nasal vaccines against hepatitis B: an update
JP2004533431A (ja) アジュバントとしてｉ型ｉｆｎを含むワクチン及びそれと関連する方法
EP4304606A1 (en) Polysaccharide adjuvants for virus vaccines
CN102813920A (zh) 一种疫苗佐剂
CN117462667B (zh) 一种复合佐剂及其在疫苗制备中的应用
WO2025084106A1 (ja) 経鼻投与による細胞性免疫の誘導方法
Maeyama et al. The mucosal adjuvanticity of the oligodeoxynucleotides containing a non-methylated CpG motif on BCG and diphtheria toxoid
CN121127263A (zh) 用于预防流感及冠状病毒感染症的混合疫苗
Yuen et al. Flu-based and PD1-based vaccines for SARS-CoV-2: abridged secondary publication
Ji et al. Enhanced immunogenicity of SARS-CoV-2 antigen with aluminum adjuvant and polysaccharide nucleic acid fraction of Bacillus Calmette Guerin
CN101410133A (zh) 作为流感病毒疫苗佐剂或免疫刺激物的dsRNA
WO2022006259A1 (en) Immunostimulatory compositions and methods
WO2014176530A1 (en) Vaccination methods
KR20210005114A (ko) 병원체에 대한 자가-약독화된 예방 및 치료 백신

Legal Events

Date Code Title Description
EEER Examination request